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Abstract: 
 
Context: The optimal treatment of acute myeloid leukemia (AML) in first complete 
remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends 
myeloablative allogeneic stem cell transplantation (alloSCT) for poor-risk but not for 
good-risk AML. AlloSCT, autologous transplant and consolidation chemotherapy are 
considered of equivalent benefit for intermediate-risk AML. We undertook a systematic 
review and meta-analysis of prospective trials evaluating alloSCT versus non-alloSCT 
therapies for AML-CR1.  
 
Objective: To quantify relapse-free survival (RFS) and overall survival (OS) benefit of 
alloSCT for AML in CR1. In subgroup analyses, RFS and OS benefit of alloSCT was 
determined for good-, intermediate- and poor-risk AML. 
 
Methods: Combining the search terms: ‘allogeneic’; ‘acut*’ and 
‘leukem*/leukaem*/leucem*/leucaem*/aml’; ‘myelo*’ or ‘nonlympho*’, we searched the 
PubMed, Embase and Cochrane Registry of Controlled Trials databases in March 2009. 
1712 articles were accessed. 
 
Study Selection: Prospective trials assigning adult AML-CR1 patients to alloSCT versus 
non-alloSCT treatment(s) based on donor availability, and reporting RFS and/or OS 
outcomes on intent-to-treat, donor versus no-donor basis were identified. 
 
Data Extraction: Two reviewers independently extracted study characteristics, 
interventions, and outcomes. Hazard ratios (HR) (with 95% CI) were determined. 
 
Data Synthesis: 24 trials and 6,007 patients were analyzed. Inter-study heterogeneity was 
not significant. Fixed effects meta-analysis was performed. HR of relapse or death with 
alloSCT for AML-CR1 was 0.80 (0.74-0.86). Significant RFS benefit of alloSCT was 
documented for poor-risk (HR 0.69 (0.57-0.84)) and intermediate-risk AML (HR 0.76 
(0.68-0.85)); but not for good-risk AML (HR 1.06 (0.80-1.42)). HR of death with 
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alloSCT for AML-CR1 was 0.90 (0.82-0.97). Significant OS benefit of alloSCT was 
documented for poor-risk (HR 0.73 (0.59-0.90)) and intermediate-risk AML (HR 0.83 
(0.74-0.93)); but not for good-risk AML (HR 1.07 (0.83-1.38)).  
 
Conclusion: AlloSCT has significant RFS and OS benefit for intermediate- and for poor-
risk AML, but not for good-risk AML in CR1. 
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Introduction: 
Achieving a cure, even for younger adult patients with de-novo acute myeloid leukemia 
(AML), remains a challenge. While over 70% of such patients will enter a first complete 
remission (CR1) after induction chemotherapy, a substantial number experience disease 
relapse. 1 Allogeneic stem cell transplantation (alloSCT) after myeloablative conditioning 
is a curative treatment option for younger AML patients in CR1. However, concerns 
regarding alloSCT related toxicity and questions regarding its benefit limit its utilization 
for patients who have attained an initial remission. Alternative therapies include intensive 
consolidation chemotherapy or autologous stem cell transplant (autoSCT). The current 
consensus, reflected in treatment guidelines of the National Comprehensive Cancer 
Network (NCCN) (V1.2009: www.nccn.org), is based on cytogenetic stratification into 
good-, intermediate-, and poor-risk AML. Patients with good-risk AML in CR1 are 
recommended chemotherapy, with autoSCT considered an acceptable alternative. 
Patients with poor-risk AML in CR1 are recommended alloSCT. There is no preferred 
therapy for patients with intermediate-risk AML in CR1: alloSCT, consolidation 
chemotherapy and autoSCT are considered of equivalent benefit. 
 
Multiple prospective trials have been undertaken to clarify the role of alloSCT for AML 
in CR1. In the context of alloSCT trial design, treatment assignment has typically been 
based on donor availability: patients with HLA matched siblings are assigned to alloSCT 
(donor arm), and those without matched siblings (or without siblings) are assigned to 
non-alloSCT therapy (no-donor arm). Although not randomized comparisons, these 
studies have nevertheless been widely accepted as providing good quality evidence of 
treatment-effect since no evidence of major bias arising from differences in biological 
and socioeconomic factors has been identified. 
 
Various prospective clinical trials, retrospective studies and systematic reviews have 
helped determine the current treatment consensus for AML in CR1. Retrospective 
analyses are prone to errors of bias and confounding, and may therefore provide 
inaccurate estimates of effect. Prospective biologic assignment trials offer a means of 
reducing such errors. However, their results have thus far not provided definitive 
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evidence to support treatment recommendations. While some individual trials have 
documented superior relapse-free survival (RFS), none has documented an overall 
survival (OS) benefit for alloSCT across all cytogenetic risk groups. Within cytogenetic 
risk groups, the evidence regarding alloSCT impact is also limited (discussed below).  
 
In order to arrive at comprehensive estimates of OS and RFS benefit from the totality of 
the clinical trial data available, we undertook a systematic literature review and meta-
analysis of all prospective biologic assignment clinical trials of alloSCT versus 
consolidation chemotherapyand/or autoSCT for AML in CR1, on an intent-to-treat (ITT) 
donor versus no-donor basis.  
 
Materials and Methods: 
 
Data Sources: We undertook searches of the Medline (PubMed), Embase and Cochrane 
Registry of Controlled Trials (updated March 2009), combining the search terms: 
‘allogeneic’; ‘acut*’ and ‘leukem*/leukaem*/leucem*/leucaem*/aml’; ‘myelo*’ or 
‘nonlympho*’. Medline (PubMed) and Embase searches were restricted to human 
studies. . Studies identified underwent title/abstract review (JK and CC), and clearly non-
relevant articles were discarded. Text review of the remainder was performed to assess 
their suitability. The bibliographies of retained articles were examined to identify 
additional studies. The abstracts of relevant scientific meetings were examined similarly 
to ensure complete review of the available data. International expert input was obtained 
to identify additional relevant trials, including those in non-English speaking countries. 
Recent reviews and meta-analyses were also accessed to identify additional studies that 
met inclusion criteria. 2-7 
 
Study Selection: Studies included were prospective trials of adults (wholly or 
predominantly) with AML in CR1 that assigned alloSCT versus a comparator of 
consolidation chemotherapy and/or autoSCT. Eligible trials reported hazard ratios (HR) 
(95% CI) for OS and/or RFS benefit on an ITT donor no-donor basis (or provided data to 
estimate HR by the method of Parmar et al). 8 When multiple publications reported on the 
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study, the most updated data was analyzed. Unadjusted HR was preferred in the analysis, 
since adjusted HR, reported in a minority of studies, was considered likely to adjust for 
different covariates per study, potentially impeding analysis across studies. Further, 
prospective biological treatment assignment was considered likely to equalize covariates 
over the large number of patients analyzed. Adjusted HR was utilized in sensitivity 
analyses. 
 
Data Extraction: The data was abstracted in a standardized format by two independent 
reviewers. The data collected for each study included: study name, study first author, 
publication year, year of initial enrollment, total number allocated to therapy, number 
assigned to donor and no-donor arm on an ITT basis, median patient age (years), median 
duration of follow-up (months), number of events (death, relapse) in each arm, study 
endpoints of OS and/or RFS benefit. We used OS and RFS (also reported as disease-free 
survival) as per the individual studies. Data on treatment related mortality (TRM) (also 
reported as non-relapse mortality) was also collected. We also collected data on therapy: 
induction therapy regimen, interim therapy regimen (if any), stem cell source (bone 
marrow (BM) or peripheral blood (PB)), alloSCT conditioning, autoSCT conditioning 
and consolidation chemotherapy regimen. Discrepancies in data extraction were resolved 
by consensus, referring back to the original article, and by contacting the study authors if 
necessary. When missing data were encountered, the primary authors were contacted to 
complete the data analysis.  
 
Quality Assessment: We assessed for quality based on the requirement for prospective 
treatment assignment, the reporting of outcomes on an ITT basis, the study size, the 
number of participating centers, the adequacy of induction chemotherapy (treatment 
regimen; percentage of patients entering CR1), and the proportion of patients allocated to 
alloSCT who underwent assigned therapy (Tables 1-3). Given the unambiguous end-
points (OS, RFS) and study treatments, we did not anticipate any impact of lack of 
blinding on outcomes. We did not explicitly score the methodologic quality of the 
included trials since the value of doing so is controversial. Ad-hoc scores may lack 
demonstrated validity, and results may not be associated with quality. 9-12 Instead, we 
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performed subgroup and sensitivity analyses, and undertook tests of interaction, as is 
widely recommended. 11-13 
 
Data Synthesis: Data analysis was done using STATA (version 7) software (STATA 
Corp, College Station, TX). Begg’s funnel plot and P value were used to investigate 
publication bias. 14 Heterogeneity was assessed by a Q statistic. 15 A Forrest plot with 
combined HR (with 95% CI) for OS and RFS benefit of alloSCT (donor) versus non-
alloSCT (no-donor) was constructed using fixed-effects meta-analysis, given lack of 
significant inter-study heterogeneity. In sensitivity analyses, random-effects meta-
analysis of DerSimonian and Laird was undertaken. 16 The threshold of significance was 
p≤0.05. 
 
We explored our findings further by additional sensitivity analyses. To assess the 
potential impact of missing OS data from studies reporting only RFS outcomes, versus 
those reporting both OS and RFS endpoints, we looked for systematic differences in RFS 
outcomes between the two groups. We also evaluated the impact of including additional 
trials that stratified treatment options by cytogenetic risk (i.e. restricting alloSCT option 
to intermediate- and/or poor-risk AML) to the initial analysis. In subgroup analyses, we 
assessed OS and RFS benefit for the cytogenetic risk subgroups: poor-, intermediate-, and 
good-risk AML. Tests of interaction across the subgroups were performed to assess 
whether benefit of alloSCT varied significantly between the cytogenetic risk categories. 
Random effects meta-analysis was also undertaken to assess the robustness of all survival 
endpoints. Adjusted HR was utilized in additional sensitivity analyses. 
 
This work was performed in accordance with the QUOROM guidelines for meta-analysis 
of randomized clinical trials. 11 
 
Results: 
 
Systematic Review: 1712 articles were identified in the initial online databases’ and 
abstract search, delineated in Figure 1. After screening titles/abstracts, 1660 non-relevant 
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articles were excluded. The remaining 52 articles were retrieved for further review. They 
were reviewed independently in a structured format, and 23 articles were discarded as 
they did not prospectively compare myeloablative alloSCT versus non-alloSCT options 
for adult patients with AML in CR1 on an ITT basis, were not assigned treatment trials, 
reported non-comparable patient cohorts, or represented repeat publications of the same 
trial. An additional relevant trial was identified by expert input.. Recent review articles 
and meta-analyses were also retrieved. 2-4 These did not yield additional relevant trials. 
 
The search identified 30 potentially relevant trials that evaluated alloSCT versus non-
alloSCT therapies (consolidation chemotherapy and/or autoSCT) for AML in CR1. 6 
trials did not report outcomes based on treatment assigned, and their non-ITT data was 
not further evaluated. 24 trials provided prospective data on OS and/or RFS outcomes 
that was extractable on an ITT donor no-donor basis. 17-33 They are included in the 
analysis, as detailed in Tables 1-3. 18 trials reported RFS outcomes across all AML 
cytogenetic risk categories. 15 trials reported OS outcomes across all AML cytogenetic 
risk categories. 6 trials restricted the alloSCT option to intermediate- and/or poor- 
cytogenetic risk AML in CR1; their cytogenetic risk stratified OS/RFS outcomes are 
included in sensitivity and subgroup analyses. No significant discrepancies between 
reviewers were noted regarding trial inclusion or data extraction. 
 
Qualitative Assessment: Overall, the studies in the analysis were considered of good 
quality, typically being prospective multi-center trials, reporting outcomes on a donor no-
donor basis analyzed on an ITT basis, performed at the national level in the US, Europe 
and Japan, and published in well respected peer-reviewed journals. They enrolled patients 
between 1982- 2006. Numbers of patients in the alloSCT and non-alloSCT arms ranged 
from 58 to 1305. Some studies combined individual patient data across multiple trials and 
reported aggregate survival endpoints. Eligible patients typically comprised adults with 
newly diagnosed AML who were <40-60 years of age, with adequate organ function and 
absence of significant concomitant disease (Table 3). Two trials included a minority 
population of pediatric patients, at 16% and 21% respectively. 22, 29 AlloSCT treatment 
adherence was reasonable for most studies, with only one trial reporting <60% 
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compliance. One study (ECOG EST3483), reported solely in summary form, with 
missing data on several parameters, was considered marginal.19  In a sensitivity analysis, 
removal of this study did not impact combined estimates of alloSCT benefit. A subset of 
the studies reported survival outcomes stratified by AML cytogenetic risk. The 
cytogenetic criteria used in different studies (e.g. SWOG/ECOG, MRC, 
EORTC/GIMEMA cytogenetic risk classification) are substantially similar, but differ in 
some minor respects. 34 Studies utilizing non-standard risk stratification were also 
analyzed by cytogenetic risk (SWOG/ECOG; MRC). 31, 33, 35  
 
The studies typically assigned patients on the basis of the availability of a HLA matched 
sibling donor for treatment allocation to the alloSCT arm. The comparator arm typically 
comprised autoSCT and/or consolidation chemotherapy. If both non-alloSCT alternatives 
were offered, randomization between the non-alloSCT arms was often performed at a 
later time point, introducing potential bias, as higher risk patients experiencing early 
relapse may not get randomized between their non-alloSCT therapies. To address this 
potential bias a donor no-donor comparison was undertaken, based solely on initial 
assignment to the alloSCT or non-alloSCT arm(s).  
 
We could not assess the quality or completeness of sibling HLA testing, or exclude 
patients listed as having no siblings from this analysis, understanding that the inclusion of 
such patients may introduce a bias into the treatment comparison. 36 However, the trials 
that expressly permitted alloSCT for patients lacking HLA matched sibling donors did 
not report significant differences between sibling and non-sibling donor outcomes. 32 This 
suggests a lack of systematic bias between outcomes in transplanted AML patients with- 
versus those without- an HLA matched sibling. 
 
The clinical trials also varied with respect to trial design and therapeutic interventions, 
with differences in induction chemotherapy (and the possibility of re-induction), interim 
chemotherapy, and consolidation chemotherapy (where applicable). AutoSCT commonly 
involved myeloablative conditioning (usually identical to that used for alloSCT) and 
autologous bone marrow (BM) infusion (some studies used peripheral blood (PB) stem 
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cells). AlloSCT comprised myeloablative conditioning (with or without radiation) 
followed by infusion of allogeneic donor BM or PB stem cells (unmanipulated or 
variably T cell depleted), with graft versus host disease prophylaxis often comprising 
cyclosporine and methotrexate. Importantly however, despite the variability in patient 
eligibility, trial design, and study interventions, inter-study heterogeneity for the OS or 
RFS endpoints was not significant. 
 
Quantitative Assessment: We subsequently undertook detailed quantitative assessments 
of the relevant studies, as discussed below. Additional sensitivity and subgroup analysis 
were also undertaken, and are described in detail. 
 
Publication Bias: We constructed Begg’s funnel plots to evaluate for publication bias. For 
RFS benefit, the plots tended to maintain a symmetric distribution, both for both the 
primary analysis of 18 trials reporting RFS outcomes across all cytogenetic risk AML 
patients (p=0.50), and for the analysis that included 6 additional trials with alloSCT 
restricted to intermediate- and/or poor-risk AML patients (p>0.99). For OS benefit, the 
plots also tended to maintain a symmetric distribution, both for the primary analysis of 15 
trials reporting OS outcomes for all cytogenetic risk AML patients (p=0.28), and for the 
analysis that included 6 additional trials with alloSCT restricted to intermediate- and/or 
poor-risk AML patients (p=0.62).  
 
AlloSCT and RFS benefit: 18 clinical trials reported endpoints of overall RFS across all 
cytogenetic risk groups. The summary hazard estimate for overall RFS benefit also varied 
between studies, ranging from 0.50 (donor better) to 1.56 (no-donor better). Inter-study 
heterogeneity was non-significant (p=0.45). A fixed-effects Forrest plot of the individual 
and combined HR (95% CI) for overall RFS benefit with alloSCT was 0.80 (0.74-0.86) 
(Figure 2). The overall estimate indicates statistically significant reduction in hazard of 
death or AML relapse with alloSCT in CR1, across all cytogenetic risk groups (p<0.01).  
 
We further evaluated the studies with sensitivity and subgroup analyses, summarized in 
Figure 2. In a sensitivity analysis, we repeated the initial RFS analysis, including 6 
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additional trials that restricted alloSCT option for intermediate- and/or poor-risk AML 
patients. The combined HR (95% CI) was 0.78 (0.73-0.84), also indicating a significant 
RFS benefit with alloSCT (p<0.01). We also assessed for systematic differences in effect 
estimates between the 15 trials that reported on both overall OS and RFS endpoints 
(group 1) versus the 3 trials that only reported on RFS endpoints (group 2). The 
combined HR (95% CI) for the 15 trials in group 1 was 0.80 (0.74-0.87); and for the 3 
trials in group 2 was 0.79 (0.61-1.02). The near identical summary effect estimate 
(HR~0.80) of group 1 and 2 indicates a lack of systematic difference in survival 
outcomes between the groups. A test of interaction between the two groups was not 
significant, as anticipated. We subsequently evaluated RFS outcomes by cytogenetic risk 
category of good-, intermediate-, and poor-risk AML. 16 trials reported RFS outcomes by 
cytogenetic risk. Good-risk AML had a combined HR of 1.06 (0.80-1.42) across 10 trials, 
indicating a lack of RFS benefit (p=0.68). Intermediate-risk AML had a combined HR of 
0.76 (0.68-0.85) across 14 trials, indicating significant RFS benefit with alloSCT in CR1 
(p<0.01). Poor-risk AML had a combined HR of 0.69 (0.57-0.84) across 14 trials, 
indicating significant RFS benefit (p<0.01). Tests of interaction between the 3 
cytogenetic risk groups were statistically significant (p<0.05), notably between good-risk 
versus poor-risk (p=0.02) and intermediate-risk AML (p=0.03), but not between poor-risk 
and intermediate-risk AML (p=0.40).  
 
Two studies reported adjusted HR(95% CI) for RFS endpoints. Use of adjusted HR did 
not change our findings regarding alloSCT RFS benefit (Figure 2). Similarly, use of 
random-effects meta-analysisdid not alter any conclusions regarding RFS benefit. In the 
18 trials that reported endpoints of overall RFS across all cytogenetic risk groups, the 
overall random-effects RFS benefit with alloSCT was 0.80 (0.74-0.86). This overall 
estimate indicates statistically significant reduction in hazard of death or AML relapse 
with alloSCT in CR1, across all cytogenetic risk groups (p<0.01). Including 6 additional 
trials that restricted alloSCT option for intermediate- and/or poor-risk AML patients, the 
combined random-effects HR (95% CI) was 0.78 (0.71-0.85), also indicating a significant 
RFS benefit with alloSCT (p<0.01). We also evaluated RFS outcomes by cytogenetic risk 
category of good-, intermediate-, and poor-risk AML. Good-risk AML had a combined 
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random-effects HR of 1.06 (0.80-1.42) across 10 trials, indicating a lack of RFS benefit 
(p=0.68). Intermediate-risk AML had a combined random-effects HR of 0.76 (0.64-0.92) 
across 14 trials, indicating significant RFS benefit with alloSCT in CR1 (p<0.01). Poor-
risk AML had a combined random-effects HR of 0.67 (0.52-0.85) across 14 trials, 
indicating significant RFS benefit of alloSCT in CR1 (p<0.01). 
 
AlloSCT and OS benefit: 15 trials reported endpoints of OS across all cytogenetic risk 
groups, and are included in the primary analysis. The summary hazard estimate for 
overall OS benefit varied between studies, ranging from 0.81 (donor better) to 1.91 (no-
donor better). Inter-study heterogeneity was non-significant (p=0.27). A fixed-effects 
Forrest plot of the individual and combined HR (95% CI) for overall OS benefit with 
alloSCT was 0.90 (0.82-0.97) (Figure 3). The overall estimate indicates statistically 
significant reduction in hazard of death with alloSCT across all cytogenetic risk AML in 
CR1 (p<0.01). 
 
We further evaluated the studies with sensitivity and subgroup analyses, summarized in 
Figure 3. In a sensitivity analysis, we repeated the initial analysis with 6 additional trials 
that provided OS alloSCT outcomes restricted to intermediate- and/or poor-risk AML 
patients. The combined HR (95% CI) was 0.87 (0.80-0.94), also indicating a significant 
OS benefit with alloSCT (p<0.01). We also evaluated OS outcomes by cytogenetic risk 
category of good-, intermediate-, and poor-risk AML. 16 trials reported OS outcomes 
stratified by cytogenetic risk. Good-risk AML had a combined HR of 1.07 (0.83-1.38) 
across 10 trials, indicating a lack of significant OS benefit (p=0.59). Intermediate-risk 
AML had a combined HR of 0.83 (0.74-0.93) across 14 trials, indicating significant OS 
benefit with alloSCT (p<0.01). Poor-risk AML had a combined HR of 0.73 (0.59-0.90) 
across 14 trials, indicating significant OS benefit with alloSCT (p<0.01). Tests of 
interaction were borderline statistically significant across the subgroups (p=0.07), 
primarily between good- versus poor-risk (p=0.02) and likely intermediate-risk AML 
(p=0.07), but not between poor-risk and intermediate-risk AML (p=0.30).  
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 Three studies reported adjusted HR(95% CI) for OS endpoints. Use of adjusted HR did 
not change our findings regarding alloSCT OS benefit (Figure 3). Similarly, use of 
random-effects meta-analysis did not alter conclusions regarding OS benefit. In the 15 
trials that reported OS endpoints across all cytogenetic risk groups, the combined 
random-effects OS benefit with alloSCT was 0.90 (0.82-1.00). This indicates statistically 
significant reduction in hazard of death with alloSCT for AML in CR1 across all 
cytogenetic risk groups (p=0.04). Including 6 additional trials that restricted alloSCT 
option for intermediate- and/or poor-risk AML patients, the combined random-effects HR 
(95% CI) was 0.87 (0.78-0.98), also indicating significant alloSCT OS benefit (p=0.02). 
We also evaluated OS outcomes by cytogenetic risk category of good-, intermediate-, and 
poor-risk AML. Good-risk AML had a combined random-effects HR of 1.06 (0.64-1.76) 
across 10 trials, indicating a lack of OS benefit (p=0.81). Intermediate-risk AML had a 
combined random-effects HR of 0.84 (0.71-0.99) across 14 trials, indicating significant 
OS benefit with alloSCT in CR1 (p=0.03). Poor-risk AML had a combined random-
effects HR of 0.60 (0.40-0.90) across 14 trials, also indicating significant OS benefit of 
alloSCT in CR1 (p=0.01). 
 
Discussion: 
 
Despite multiple prospective studies over the past two decades, the role of alloSCT for 
adult AML-CR1 patients remains ill-defined. A meta-analysis of 5 prospective trials by 
Yanada et. al. indicated an overall OS benefit with alloSCT (p=0.04), and meta-
regression suggested that the OS benefit may be restricted to poor-risk AML (p=0.12). 5 
In addition to the limited number of trials and the use of indirect evidence (meta-
regression) to indicate possible cytogenetic subgroup benefit, double counting of alloSCT 
data from individual studies that reported alloSCT versus autoSCT and consolidation 
chemotherapy outcomes separately remains an unaddressed source of bias. An ITT donor 
no-donor analysis offers a better means to address such concerns. Cornelissen et. al. 
combined donor no-donor data from four cooperative groups (BGMT, HOVON/SAKK, 
MRC and EORTC) in a meta-analysis to demonstrate a statistically significant survival 
benefit to alloSCT; and in cytogenetic subgroup analyses, an OS benefit was documented 
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for intermediate-risk, but not poor-risk AML. 30 The limited number of trials assessed 
(e.g. omission of EORTC AML8A study) has likely precluded general acceptance of their 
meta-analysis. 
 
Thus, current recommendations from NCCN, and from the American Society of Blood 
and Marrow Transplantation (ASBMT), based on literature review and expert consensus, 
stratify treatment by cytogenetic risk, and state that there is a survival advantage for 
alloSCT in patients <55 years with poor-risk AML-CR1; that there is insufficient 
evidence to routinely recommend alloSCT for patients with intermediate-risk AML-CR1; 
and that there is no survival advantage for alloSCT in good-risk AML-CR1. 4 The direct 
evidence supporting these recommendations remains limited, as previously discussed. In 
part, this may be because all clinical trial data has not been systematically assessed. 
Quantitatively integrating data from all available trials will likely enhance our 
understanding of the role of alloSCT for AML-CR1. The robustness of any conclusions 
can be systematically assessed in secondary analyses.  
 
To comprehensively assess the utility of upfront alloSCT for AML-CR1, we therefore 
undertook a systematic literature review and meta-analysis of published data from 
clinical trials allocating alloSCT versus non-alloSCT options (consolidation 
chemotherapy and/or autoSCT) for such patients. We focused on an ITT analysis based 
on donor availability in order to capture information from all AML patients who were 
evaluated for upfront alloSCT with a donor search as part of a prospective trial. Prior 
meta-analyses have shown that survival after autoSCT is equivalent to that with 
consolidation chemotherapy for AML-CR1 patients, supporting the decision to combine 
the non-alloSCT treatment options in a single no-donor category. 6, 7, 37 
 
The systematic literature search identified 24 relevant trials comparing alloSCT versus 
non-alloSCT treatment for AML-CR1, none of which individually reported an alloSCT 
OS benefit across all cytogenetic risk groups (Table 1), possibly owing to limited sample 
size (power calculations were not routinely described in the study reports). Enrolling 
patients between 1982 and 2006, the trials are all mature, and further long-term follow-up 
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is unlikely to yield substantially different results. The trials varied with regards to patient 
eligibility, study trial design, cytogenetic risk classification and specific interventions 
used (Table 2). Importantly however, inter-study heterogeneity was not significant for OS 
or RFS endpoints, indicating that the impact of study differences was limited.  
 
We considered the effect, if any, of differences in cytogenetic risk classification between 
studies. Such differences, if significant, may be anticipated to increase the between-
studies heterogeneity for each cytogenetic risk group’s endpoints, which was not 
observed. This is likely because the various cytogenetic risk classification schemes are 
fairly similar, although not identical. 30 While we could not assess the impact of such 
differences directly, individual prospective studies that directly compared cytogenetic 
risk classifications (SWOG/ECOG, EORTC/GIMEMA, MRC) documented highly 
concordant effect estimates, independent of the classification schema used. 25, 26 It is 
therefore unlikely that variability between cytogenetic risk classifications significantly 
impacted our analysis. 
 
We also considered the role of treatment compliance. This likely disproportionately 
impacts the alloSCT (donor) arm, as a significant fraction of patients with donors did not 
receive alloSCT. Such crossover, analyzed on an ITT basis, is anticipated to reduce the 
observable survival benefit of alloSCT. Typically, the studies reported an alloSCT 
compliance rate of >60%, which is considered reasonable for such prospective trials (one 
trial reported an alloSCT compliance rate of 55%, and in a sensitivity analysis, its 
removal did not impact the overall conclusions). In addition, the impact of salvage 
alloSCT after AML relapse cannot be estimated, but likely diminishes any observable OS 
benefit of upfront alloSCT. Further, the inclusion of older trials, some over two decades 
old, likely also biases against alloSCT, since advances in supportive care (e.g. growth 
factors; improved anti-infective strategies; better prophylaxis/therapy of graft-versus-host 
disease) and transplantation methodology (e.g. PBSC) are considered responsible for 
improvement in alloSCT outcomes.  
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Our primary finding is that the totality of the prospective trial data indicates statistically 
significant RFS and OS benefit for alloSCT in adult AML-CR1. This conclusion is 
supported by a variety of sensitivity and subgroup analyses as reported above. 
Additionally, our analyses indicate that alloSCT benefit likely varies by AML 
cytogenetic risk. We document significant RFS and OS benefit for alloSCT in 
intermediate- and poor-risk AML, and a lack of significant RFS or OS benefit for good-
risk AML. With regards comparative absolute survival, anticipating 5-year OS rates in 
the control (non-alloSCT) arm of 45% and 20% for intermediate- and poor-risk AML 
respectively, patients assigned alloSCT in CR1 would likely experience OS rates of 54% 
and 42% for intermediate- and poor-risk AML respectively. 
 
There are limitations to our analysis. We are aware of relevant studies that have not yet 
been reported (e.g. UK MRC AML 12/15; GOELAM2). 38-40 As a meta-analysis of the 
published literature, we extracted summary statistics (HR) from individual studies to 
determine combined estimates. Dependence on published articles limits the level of detail 
that can be captured regarding sub-groups that may have greater or lesser benefit from 
alloSCT. We could not assess outcomes for clinically relevant subgroups other than 
cytogenetic risk. For instance, patient age is a likely relevant factor, and some, though not 
all, studies have indicated improved alloSCT outcomes in younger adults. 26, 29, 30 The 
median patient age in most trials in this report is in the 30s, and while the age eligibility 
was up to age 60 years in individual studies, it remains unclear if older eligible patients 
obtained an equivalent benefit.  
 
With regards treatment toxicity, we have summarized available TRM data for individual 
studies (Table 3). However, the variable and limited data reported precluded a more 
formal analysis, and highlights the need for more systematic reporting of this important 
endpoint in the future. We also note that while patients in this analysis predominantly had 
de-novo AML, eligibility criteria in some studies permitted enrollment of patients with 
prior MDS or therapy-related AML. Finally, the impact of comorbidities could not be 
assessed, since trial eligibility criteria disbarred entry to such patients. Nonetheless, for 
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treatment outside of the research setting, it has significant impact on alloSCT outcomes in 
AML. 41, 42  
 
A meta-analysis of individual patient data from the relevant clinical trials is a way to 
obtain more complete estimates of OS and RFS benefit with alloSCT; and to assess the 
impact of additional factors like patient age. A broad overview of transplant for AML-
CR1 utilizing individual patient data is currently being conducted by the Acute Leukemia 
Stem Cell Transplant Trialists’ Collaborative Group. Nonetheless, our quantitative 
analysis of data from 24 trials comprising 6,007 prospectively assigned patients provides 
the most complete estimate of alloSCT benefit available. It enables an informed 
assessment of the role of upfront alloSCT for adult AML patients in CR1. 
 
Cytogenetic and molecular risk profiling in AML is an evolving field, and can further 
stratify outcomes within a known cytogenetic risk group. For instance, Schlenk et. al. 
from the German Austrian AML Study Group (AMLSG) reported that for patients with 
cytogenetically normal AML (who would be classified as intermediate-risk), alloSCT 
was beneficial for those with either a FLT3 internal tandem duplication (FLT3-ITD), or 
in the absence of FLT3-ITD, for those without mutations in NPM1 and CEBPA; while 
for the subgroup with mutations in NPM1 and without FLT3-ITD there was no apparent 
benefit to having a matched sibling. 31 However, such novel genetic lesions, as well as 
whole genome analyses, RNA and microRNA profiles that have the potential to further 
refine AML risk, are not in routine clinical use. 43, 44  
 
The dilemma of how to best treat adult AML-CR1 patients with a known cytogenetic risk 
profile therefore remains. While enrollment in therapeutic trials is to be encouraged, our 
findings provide evidence to guide clinical decision-making and future trial design. We 
find evidence to support treatment based on AML cytogenetic risk. We conclude that 
alloSCT does not provide significant benefit for good-risk AML in CR1; and that 
alloSCT offers significant RFS and OS benefits for intermediate- and poor-risk AML in 
CR1. However, within these general guidelines, there remains a need to further 
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individualize the alloSCT decision, based on factors like patient age, comorbidity, and 
the presence of additional molecular lesions. 
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Table and Figure Legends: 
 
Table 1: Summary of clinical trials evaluating alloSCT benefit for AML in CR1.  
The study ID, first author, year of publication, enrollment period, median patient age 
(years) at enrollment in the donor and no-donor arms (with range), median duration of 
follow-up (months) (with range), and study conclusions regarding overall survival (OS) 
and relapse-free survival (RFS) benefit are also shown for each study. 
 
* this study, reported solely in abstract form, was considered marginal. Its removal did 
not impact conclusions regarding alloSCT survival benefit. 
α very few patients under 15 were enrolled, per the study report 
β manuscript submitted for publication 
χ no significant difference between donor and no-donor groups, per the study report 
δ described as a study of adult AML 
ε pooled cytogenetic risk stratified results from four cooperative groups are presented, 
indicating RFS and OS alloSCT benefit in intermediate-risk AML-CR1, and RFS but not 
OS benefit in poor-risk AML-CR1. See text for details. 
φ alloSCT benefit for intermed-risk AML-CR1 documented in AMLHD98A study 
γ JALSG risk stratified outcomes were restratified by cytogenetic risk 
 
Table 2: Summary of clinical trials evaluating alloSCT benefit for AML in CR1: 
Therapies utilized. 
Further information on the studies listed in Table 1 is provided, to better describe study 
interventions. Information on the donor vs. no-donor treatment arms is provided.  
 
* autologous conditioning was essentially identical 
 
Acronyms/Abbreviations: 
Allo: Myeloablative allogeneic stem cell transplantation 
AraC: Cytarabine 
Amsa: Amsacrine 
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Auto: Autologous stem cell transplantation 
Bu: Busulfan 
CC: Consolidation chemotherapy 
Cy: Cyclophosphamide 
Dnr: Daunorubicin 
FLAG: Fludarabine; AraC; GCSF 
GMCSF: Granulocyte/Macrophage growth factor 
hiDAC: high dose AraC 
Ida: Idarubicin 
Mel: Melphalan 
midDAC: intermediate-dose AraC 
Mito: Mitoxantrone 
NA: Not applicable 
NR: Not reported 
Pred: Prednisone 
Rbz: Rubidazone 
TBI/TLI: Total body irradiation/Total lymphoid irradiation (Gray) 
Tg: Thioguanine 
Vcr: Vincristine 
VP: VP16/Etoposide 
 
Table 3: Summary of clinical trials evaluating alloSCT benefit for AML in CR1: 
Additional information regarding Trial Design, Entry Criteria, Response and 
Toxicity. 
Additional information on the number of participating institutions, initial complete 
remission (CR1) rates, trial entry criteria, source of allogeneic stem cells, proportion of 
patients who underwent scheduled alloSCT, and treatment related mortality (TRM), for 
the studies listed in Table 1 is provided, when available from the original publications. 
The TRM data was variably reported, and had to be inferred for some studies.  
 
 
Acronyms/Abbreviations: 
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APL: Acute promyelocytic leukemia 
BMSC: Bone marrow stem cell 
Card: Cardiac 
CBF: Core binding factor 
CNS: Central nervous system 
Hep: Hepatic 
Infxn: Infection 
MDS: Myelodysplastic syndrome 
Metab: Metabolic 
Neuro: Neurologic 
NR: Not reported 
PBSC: Peripheral blood stem cell 
Pulm: Pulmonary 
TCD: T-cell depleted 
 
Figure 1: Search strategy flow chart.  
The Embase, Pubmed, Cochrane and Abstract search, and the process of identifying 
relevant clinical trials for inclusion in the meta-analysis are shown.  
 
* the most updated report was included 
 
Figure 2: Forrest plot of relapse-free survival (RFS) benefit of alloSCT in AML-
CR1.  
The individual reports are indicated on the Y-axis. The summary effect estimate (HR) for 
individual study reports are indicated by black rectangles (the size of the rectangle is 
proportional to the study weight), with the lines representing 95% CI. The overall 
summary effect estimate (HR) and 95% CI are indicated by the diamond. Overall 
estimates after additional sensitivity and sub-group analyses are shown below. The 
corresponding values for number of patients at-risk in the donor versus no-donor arm and 
HR (95% CI) are indicated alongside. The number trials combined per pooled estimate 
are also indicated. 
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* studies only reporting RFS endpoints 
 
Figure 3: Forrest plot of overall survival (OS) benefit of alloSCT in AML-CR1.  
The individual reports are indicated on the Y-axis. The summary effect estimate (HR) for 
individual study reports are indicated by black rectangles (the size of the rectangle is 
proportional to the study weight), with the lines representing 95% CI. The overall 
summary effect estimate (HR) and 95% CI are indicated by the diamond below. Overall 
estimates after sensitivity and sub-group analyses are shown below. The corresponding 
values for number of patients at-risk in the donor versus no-donor arm and HR (95% CI) 
are indicated alongside. The number trials combined per pooled estimate are also 
indicated. 
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Archimbaud20 
(1994) LYLAM85 1985-1990 31 (19-39) 31 (17-39) 63 (NR) 
Overall: RFS-No; OS-No 
Cyto stratfied: NR 
Hewlett21  
(1995) S8125 1982-1986 28 (16-49) 32 (13δ-39) 111 (83-142) 
Overall: RFS-No; OS-No 
Cyto stratified: NR 
Sierra22  
(1996) CETLAM88 1988-1993 31 (1-50) 29.5 (1-50) 98 (5-106) 
Overall: RFS-No; OS-No 
Cyto stratified: NR 
Harousseau23 
(1997) GOELAM1 1987-1994 NRχ (15-40) NRχ (15-40) 62 (23-103) 
Overall: RFS-No; OS-NR 
Cyto stratified: NR 
Keating24  
(1998) EORTC/GIMEMA-AML8A 1986-1993 32 (13α-45) 31 (11α-45) 69.6 (NR) 
Overall: RFS-Yes; OS-No 
Cyto stratified: NR 
Slovak25  
(2000) E3489/S9034 1990-1995 34 (18-54) 39 (16-55) 57.6 (8-90) 
Overall: RFS-No; OS-No 
Cyto stratified: RFS-No; OS-Yes (poor-risk) 
Suciu26  
(2003) EORTC/GIMEMA-AML10 1993-1999 35 (15-45) 33 (15-45) 48 (NR) 
Overall: RFS-Yes; OS-No 
Cyto stratified: RFS-Yes;OS-Yes (poor-risk) 
Brunet27  
(2004) CETLAM94 1994-1999 37 (16-50) 37 (16-50) 54 (1-85) 
Overall: NA (alloSCT option for non-fav risk)  
Cyto stratified: RFS-No; OS-No 
Jourdan28  
(2005) BGMT 84/87/91/95 1984-2001 34 (15-45) 33.5 (15-45) 114 (29-222) 
Overall: RFS-Yes; OS-No 
Cyto stratified: RFS-NR; OS-NR 
Burnett29  
(2006) MRC AML10 1988-1995 NR (0-45+) NR (0-45+) 142 (26-193) 
Overall: RFS-Yes; OS-No  
Cyto stratified: RFS-Yes; OS-Yes (intermed-risk) 
Cornelissen30 
(2007) HOVON/SAKK AML4/29/42 1987-2003 39 (15-55) 39 (16-55) 63 (NR) 
Overall: RFS-Yes; OS-No  
Cyto stratified: RFS-NRε; OS-NRε 
Schlenk31  
(2008) 
AMLHD93 
AMLHD98A 
1993-1998 
1998-2004 
44 (17-59) 
48 (16-60) 
47 (16-60) 
47 (18-60) 
106 (74-178) 
73 (11-118) 
Overall: NA (alloSCT option for non-fav risk) 
Cyto stratified: RFS-Yes; OS-Yes (intermed-risk) φ 
Basara32  
(2009) OSHO AML96/02 1996-2006 42 (17-59) 51 (16-60) 19 (4-94) 
Overall: NA (alloSCT option for poor-risk) 
Cyto Stratified: RFS-Yes; OS-Yes (poor-risk) 
Sakamaki33 JALSG AML97 1997-2001 37 (16-50) 36.5 (15-50) 74 (19-104) Overall: NA (alloSCT for non-fav JALSG risk) 
(2009)β Cyto stratifiedγ: RFS-No; OS-No 
Table 1: Summary of clinical trials evaluating alloSCT benefit for AML in CR1. 
α very few patients under 15 were enrolled, per the study report 
β manuscript submitted for publication 
χ no significant difference between donor and no-donor groups, per the study report 
δ described as a study of adult AML 
ε pooled cytogenetic risk stratified results from four cooperative groups are presented, indicating RFS and OS alloSCT benefit in 
intermediate-risk AML-CR1, and RFS but not OS benefit in poor-risk AML-CR1. See text for details. 
φ alloSCT benefit for intermed-risk AML-CR1 documented in AMLHD98A study 
γ JALSG risk stratified outcomes were restratified by cytogenetic risk 
 Study Author 
Donor v No-donor 
Arms 
Induction Therapy 
(optional) Interim Therapy Ablative Allogeneic Conditioning* Consolidation Chemotherapy 
Ferrant17 Allo v Auto Dnr+AraC->(hiDAC) Dnr+AraC Cy+AraC+TBI(8Gy) NA 
Schiller18 Allo v CC Dnr+AraC±Tg None Cy/AraC+TBI(11Gy)/TLI±AraC/Mito hiDAC+Dnr/Mito/VP x1-3 
Cassileth19 Allo v CC Dnr+AraC+Tg x1-2 None NR hiDAC+Amsa x1 
Archimbaud20 Allo v CC Dnr+AraC+Tg hiDAC+Amsa Cy+Bu;Cy+TBI(10-12Gy) Dnr+AraC+Tg v midDAC+Dnr 
Hewlett21 Allo v CC 
Dnr+AraC+Tg+Vcr+Pred 
x1-2 None Cy+TBI(12Gy) 
Dnr+AraC+Tg+Vcr+Pred x2->maint v 
late intensification 
Sierra22 Allo v Auto Dnr+AraC+VP x1-2 
hiDAC+Mito-> 
hiDAC+Amsa 
Cy+TBI(12-14Gy); Bu+Mel; 
Bu+Cy±VP;Bu+VP NA 
Harousseau23 Allo v Auto v CC Ida/Rbz+AraC x1-2 
D:Amsa+AraC; 
ND:hiDAC+Ida/Rbz Bu+Cy;Cy+TBI;Various+TBI Amsa+VP 
Keating24 Allo v Auto v CC Dnr+AraC±GMCSF x1-2 midDAC+Amsa Cy+TBI(10-12Gy);Bu+Gy hiDAC 
Slovak25 Allo v Auto v CC Ida+AraC x1-2 Ida+AraC Bu+Cy hiDAC 
Suciu26 Allo v Auto 
Dnr/Ida/Mito+AraC+VP  
x1-2 Dnr/Ida/Mito+midDAC Cy+TBI(12Gy);Bu+Cy NA 
Brunet27 
Allo v Auto(Non 
favorable risk) Ida+AraC+VP x1-2 midDAC+Mito Cy+TBI(12-14Gy); Bu+Cy NA 
Jourdan28 Allo v Auto ± v CC Dnr+AraC x1-2 Dnr+AraC Cy+TBI(12Gy);Bu+Cy hiDAC 
Burnett29 Allo v Auto v Obs Dnr+AraC+Tg/VP x2 
Amsa+AraC+VP-> 
midDAC+Mito Cy+TBI(7.5-14Gy); Bu+Cy NA 
Cornelissen30 Allo v Auto v Obs 
Dnr/Ida+AraC-> 
Amsa+midDAC ND:Mito+VP NR NA 
Schlenk31 
Allo v CC (int-risk) 
(HD93, 98A) or 
Auto (poor-risk) 
(HD93) Ida+AraC+VP x2 hiDAC+Mito Cy+TBI(12-14Gy); Bu+Cy hiDAC+Mito 
Basara32 
Allo v CC/Auto 
(poor risk) 
Ida+midDAC-> 
(midDAC+Mito/FLAG+Mito)
AML96: 
Ida+midDAC/Mito Cy+TBI(12Gy) AML96:midDAC; AML02:Ida+midDAC 
Sakamaki33 
Allo v CC (int/poor 
JALSG risk) Ida+AraC x1-2 None Per Institutional Standard AraC+Anthracycline ± maint 
Table 2: Summary of clinical trials evaluating alloSCT benefit for AML in CR1: Therapies utilized. 
 
 
Study Author 
Multi-
center 
CR1 
% Study Entry Criteria 
Allogeneic 
Stem Cells 
Underwent 
AlloSCT  
% 
TRM-
Donor 
% 
TRM 
No-donor 
% 
Risk stratified 
Treatment? 
Ferrant17 Yes 89 
de-novo AML; <56y incl pediatric; 
no prior MDS; Cr<3 BMSC 83 5 27 No 
Schiller18 No 80 newly dx AML; 16-45y; no renal/hep/card dz 
BMSC 
(some TCD) 89 32 4 No 
Cassileth19 Yes 71 AML; 16-41y BMSC NR NR NR No 
Archimbaud20 No 74 newly dx AML; 15-40y; BMSC 74% 30 13 No 
Hewlett21 Yes 70 AML; no prior Rx; <50y adult; no CNS dz BMSC 64 35 5 No 
Sierra22 Yes 75 
AML; <51y includes pediatric; 
no prior Rx/MDS; no severe concomitant dz BMSC 55 42 0 No 
Harousseau23 Yes 73 
de-novo AML; 15-40y; 
no prior Rx/MDS; no renal/hep/card dz BMSC 83 22 5 No 
Keating24 Yes 67 
newly dx AML; 10-45y; no prior Rx/MDS; 
no renal/hep/card/neuro dz 
BMSC 
(some TCD) 61 21 11 No 
Slovak25 Yes 71 
AML; 16-55y; no prior Rx; 
no infxn/renal/hep/card/ dz BMSC 70 21 7 No 
Suciu26 Yes 72 
AML; 15-46y; no prior Rx/MDS/APL; 
no renal/hep/card/pulm/neuro dz 
BMSC 
(some TCD) 69 20 5 No 
Brunet27 Yes 72 
AML; 16-50y; no prior Rx/MDS/APL/CBF; 
no severe concomitant dz 
BMSC/PBSC 
(some TCD) 85 18 3 
Yes: non-favorable 
risk  
Jourdan28 Yes 80 
AML; 15-45y; 
no prior MDS/APL (post '95) 
BMSC/PBSC 
(some TCD) 91 25 7 
No (few good-risk 
enrolled post ‘95) 
Burnett29 Yes 83 
AML; ≤55y includes pediatric; 
few 'good risk cytogenetics' (post '94) BMSC 63 23 12 
No (few good-risk 
enrolled post ‘94) 
Cornelissen30 Yes 85 
newly dx AML; 15-50 or 55y; no APL; 
no severe metab/card/pulm/neuro dz BMSC 82 25 5 No 
Schlenk31 Yes 
73 
70 
primary AML; 16-60y; no MDS/APL/CBF; 
no renal/hep/card dz BMSC/PBSC
83 
80 
19 
23 
10 
8 
Yes: intermed-
/poor-risk 
Basara32 Yes 56 
AML; 16-60y; no APL/CBF/ intermed-risk; 
no hep/card/pulm dz 
PBSC 
(some TCD) 72 15 4 Yes: poor-risk 
Sakamaki33 Yes 75 
untreated AML; 15-50y; no JALSG good-risk; 
no prior Rx/MDS; no severe concomitant dz BMSC/PBSC 76 16 17 
Yes: intermed-
/poor-JALSG risk 
Table 3: Summary of clinical trials evaluating alloSCT benefit for AML in CR1: Additional information regarding Trial Design, Entry 
Criteria, Response and Toxicity. 
